Annexin Pharmaceuticals
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Annexin Pharmaceuticals is a Swedish privately held biotech company[1][2] developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).
References[edit]
- ^ Martz, Lauren (May 26, 2014). "Annexin: Attenuating vascular inflammation" (PDF). BioCentury: A18. Retrieved 1 February 2015.
- ^ "Allabolag.se - Företagsinformation om alla Sveriges bolag".
External links[edit]
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |